Combination Therapy Shows Promise for Chronic Myeloid Leukemia
According to the results of a new study published in Science Translational Medicine, a combination regimen consisting of a BCR-ABL tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor may one day result in a cure for chronic myeloid leukemia.
January 03, 2017
Radiation Plus Chemotherapy Improves Survival From Low-Grade Gliomas
A new study has shown that patients with grade 2 gliomas who are treated with radiation therapy plus a combination of chemotherapy have better survival than patients treated with radiation alone. The findings were published in the New England Journal of Medicine.
June 01, 2016
FDA Approves Carfilzomib in Combination With Lenalidomide and Dexamethasone for Treatment of Relapsed Multiple Myeloma
On July 24, 2015, the U.S. Food and Drug Administration approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
July 24, 2015
FDA Approves Combination of Mekinist and Tafinlar for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) granted accelerated approval to trametinib (Mekinist tablets, GlaxoSmithKline, LLC) and dabrafenib (Tafinlar capsules, GlaxoSmithKline, LLC) for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test.
January 10, 2014